TREATMENT FOR ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION: PROGRESS AND PERSPECTIVES


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The main line of treatment for acute coronary syndrome with ST-segment elevation is to restore blood flow along infarct-related artery by thrombolytic therapy or percutaneous coronary intervention (PCI) as soon as possible. The choice of a reperfusion technique is determined by the capacities of a specific health care facility or a possibility of referring a patient to an institution that is able to perform PCI. The time of the onset of reperfusion can be reduced by prehospital thrombolysis. Due to the complexity of performing emergency PCI in our country, this strategy may become saving to an enormous number of patients.

About the authors

M Gilyarov

Email: gilarov@rambler.ru <mailto:gilarov@rambler.ru>

N Novikova

A Ivanov

A Syrkin

M Gilyarov

Sechenov Moscow Medical Academy

Sechenov Moscow Medical Academy

N Novikova

Sechenov Moscow Medical Academy

; Sechenov Moscow Medical Academy

A Ivanov

Sechenov Moscow Medical Academy

Sechenov Moscow Medical Academy

A Syrkin

Sechenov Moscow Medical Academy

; Sechenov Moscow Medical Academy

References

  1. Abdel-Latif A. et al. Adult Bone Marrow-Derived Cells for Cardiac Repair // Arch. Intern. Med. - 2007; 167: 989-997.
  2. Boersma E. et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour // Lancet. -1996; 348: 771-775.
  3. Chen J., Normand SI. Myocardial infarction and quality of care // CMAJ.-2008; 21; 179: 875-876.
  4. De Luca G. et al. Time Delay to Treatment and Mortality in Primary Angioplasty for Acute Myocardial Infarction: Every Minute of Delay Counts // Circulation. - 2004; 109:1223-1225.
  5. Gersh B. J. et al. Pharmacological Facilitation of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Is the Slope of the Curve the Shape of the Future? // JAMA. - 2005; 293: 979-986.
  6. Giraldez R.R., Nicolau J.C., Corbalan R. et al. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis // Eur. Heart. J. - 2007; 28:1566-1573.
  7. International Experts Workshop on Early Treatment Strategies for Acute Myocardial Infarction. Budapest, July 4-6, 2008. <http://www.metalyse>.com/img/ download/ mi_news_budapest08.pdf 8. Kent et al. Comparison of Mortality Benefit of Immediate Thrombolytic Therapy Versus Delayed Primary Angioplasty for Acute Myocardial Infarction
  8. // Am. J. Cardiol. - 2007; 99: 1384-1388.
  9. Peters R.J., Joyner С, Bassand J.P. et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial // Eur. Heart. J. - 2008; 29: 324-331.
  10. Steg et al. Impact of Time to Treatment on Mortality After Prehospital Fibrinolysis or Primary Angioplasty: Data From the CAPTIM Randomized Clinical Trial // Circulation. - 2003; 108: 2851-2856.
  11. Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) <http://>www.cardiosource.com/ <http://www.cardiosource.com/>clinicaltrials/trial.asp?triallD=1661
  12. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation // Eur. Heart J. - 2008; 29: 2909-2945.
  13. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction // Lancet. - 2001; 358:605-613.
  14. Wallentin L, Goldstein P., Armstrong P.W. et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction // Circulation. - 2003; 108:135-142.
  15. White H.D., Braunwald E., Murphy S.A. et al. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25 // Eur. Heart. J. - 2007; 28: 1066-1071.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies